Last $47.06 USD
Change Today +0.23 / 0.49%
Volume 194.7K
NUVA On Other Exchanges
As of 2:54 PM 01/27/15 All times are local (Market data is delayed by at least 15 minutes).

nuvasive inc (NUVA) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/8/15 - $51.23
52 Week Low
04/30/14 - $31.35
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NUVASIVE INC (NUVA)

nuvasive inc (NUVA) Related Businessweek News

No Related Businessweek News Found

nuvasive inc (NUVA) Details

NuVasive, Inc., a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for the spine. Its products focus on applications for spine fusion surgery. The company’s principal product offering includes a minimally disruptive surgical platform, known Maximum Access Surgery (MAS) that includes its proprietary software-driven nerve detection and avoidance systems, NVM5 and NVJJB, and intra-operative monitoring (IOM) support; MaXcess, an integrated split-blade retractor system; and various specialized implants. Its spine surgery product line offerings comprise products for the thoracolumbar and the cervical spine, which are primarily used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. The company’s biologic product line offerings used to aid the spinal fusion process or bone healing consist of allograft (donated human tissue); Osteocel Plus, an allograft cellular matrix containing viable mesenchymal stem cells; FormaGraft, a collagen synthetic product; and AttraX, a synthetic bone graft material. It also provides IOM services for insight into the nervous system during spine and other surgeries. In addition, the company is developing proprietary total disc replacement devices, which include XL-TDR, a mechanical total disc replacement for lateral lumbar spine applications; and the PCM device for cervical spine applications. It sells its products through independent sales agencies, directly-employed sales shareowners, and distributors to surgeons and hospitals in the United States and internationally. NuVasive, Inc. was founded in 1997 and is headquartered in San Diego, California.

1,358 Employees
Last Reported Date: 03/3/14
Founded in 1997

nuvasive inc (NUVA) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $900.0K
President and Chief Operating Officer
Total Annual Compensation: $520.0K
President of U.S. Sales and Services
Total Annual Compensation: $375.0K
Executive Officer
Total Annual Compensation: $550.0K
Special Advisor
Total Annual Compensation: $482.5K
Compensation as of Fiscal Year 2013.

nuvasive inc (NUVA) Key Developments

NuVasive, Inc. Announces Management Changes

NuVasive, Inc. announced changes to its leadership team designed to enhance the company's organizational alignment and accelerate its market share-taking strategy in the global spine market. Pat Miles, NuVasive's current President of Global Products and Services, will assume an expanded role as President and Chief Operating Officer. In this new role, Mr. Miles will continue to be responsible for leadership and management of global products and services. In addition, he will take on NuVasive's operational duties, including customer fulfillment, manufacturing, supply chain management and quality engineering. The company also announced that NuVasive's Chief Operating Officer Keith Valentine will step down from that role and be leaving the company effective April 30, 2015. Mr. Valentine is committed to working with the company to ensure a seamless transition of responsibilities over the coming months. Mr. Miles' newly expanded role as President and Chief Operating Officer is the product of 14 years of service to NuVasive.

NuVasive, Inc. Provides Preliminary Results for 2014; Provides Revenue Guidance for 2015

NuVasive, Inc. provides preliminary results for 2014. NuVasive anticipates full-year 2014 revenue will approximate $761 million. Previously issued guidance for this metric was approximately $755 million. NuVasive also anticipates preliminary fourth quarter 2014 revenue performance of approximately $203 million. The company also anticipates that full-year 2014 non-GAAP operating margin will exceed previously issued guidance of approximately 16.5%, with guidance alone reflecting more than 150 basis points of expansion in operating margin versus the full-year 2013. Driving this anticipated full-year 2014 non-GAAP operating margin performance is NuVasive's preliminary anticipation of fourth quarter 2014 non-GAAP operating margin of approximately 20%. The company provides revenue guidance for 2015. NuVasive expects full-year 2015 revenue to grow approximately 6% year-over-year to $810 million, which includes approximately $8 million in currency headwinds.

NuVasive, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 09:00 AM

NuVasive, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 09:00 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Alexis V. Lukianov, Chairman and Chief Executive Officer.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NUVA:US $47.06 USD +0.23

NUVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CONMED Corp $47.61 USD -0.19
Cyberonics Inc $57.38 USD -0.1925
Globus Medical Inc $24.77 USD +0.26
Integra LifeSciences Holdings Corp $57.57 USD -0.02
Thoratec Corp $36.62 USD -0.33
View Industry Companies

Industry Analysis


Industry Average

Valuation NUVA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.9x
Price/Book 3.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NUVASIVE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at